Related Experiment Video
Updated: Jun 17, 2026
11:13
Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
Published on: August 19, 2015
Layered bionanocomposites as carrier for procainamide.
Bhavesh D Kevadiya1, Ghanshyam V Joshi, Hari C Bajaj
1Discipline of Inorganic Materials and Catalysis, Central Salt and Marine Chemicals Research Institute, Council of Scientific and Industrial Research (CSIR), Gijubhai Badheka Marg, Bhavnagar 364 002, Gujarat, India.
International Journal of Pharmaceutics
|January 16, 2010
Summary
This study developed a novel drug delivery system using procainamide hydrochloride (PA) intercalated in montmorillonite (MMT), compounded with alginate (AL) and chitosan (CS). This system effectively controls drug release in gastric and intestinal environments.
Area of Science:
- Materials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Procainamide hydrochloride (PA) is an antiarrhythmic drug.
- Montmorillonite (MMT) is a clay mineral with potential for drug delivery applications.
- Developing effective drug delivery systems is crucial for improving therapeutic outcomes.
Purpose of the Study:
- To intercalate procainamide hydrochloride (PA) into montmorillonite (MMT) to create a novel drug delivery system.
- To modify the PA-MMT composite with alginate (AL) and chitosan (CS) to control drug release.
- To investigate the in vitro release characteristics of PA from the developed nanocomposite beads.
Main Methods:
- Intercalation of PA into MMT under various reaction conditions.
- Characterization of intercalated PA-MMT using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), and differential scanning calorimetry (DSC).
- Preparation of PA-MMT-AL and PA-MMT-AL-CS nanocomposite beads and analysis of their surface morphology via scanning electron microscopy (SEM).
Main Results:
- Successful intercalation of PA within MMT galleries confirmed by XRD, FT-IR, and DSC.
- Alginate (AL) and chitosan (CS) coatings effectively retarded PA release in simulated gastric environments.
- Controlled release of PA in simulated intestinal environments was observed, with release profiles fitting Higuchi and Korsmeyer-Peppas models, indicating diffusion-controlled release.
Conclusions:
- The developed PA-MMT-AL-CS nanocomposite system shows promise as a controlled drug delivery device for procainamide hydrochloride.
- The combination of MMT, alginate, and chitosan offers a strategy for modulating drug release kinetics.
- The study highlights the potential of nanocomposite materials for targeted and sustained drug delivery applications.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:17Pore Transport and Ion-Pair Transport
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:19Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...